John M. Leonard, M.D., serves as the President and Chief Executive Officer at Intellia Therapeutics Inc., a leading biotechnology company focused on developing novel CRISPR-based gene editing therapies. Dr. Leonard brings a wealth of experience to his role, having previously served as the Chief Scientific Officer and Senior Vice President of Pfizer Inc., where he played a pivotal role in the development and advancement of the company's scientific strategy. His tenure at Pfizer saw the successful launch of several groundbreaking therapies, underscoring his ability to translate scientific innovation into tangible medical solutions. Prior to his time at Pfizer, Dr. Leonard held various leadership positions at other prominent pharmaceutical companies, including Abbott Laboratories and GlaxoSmithKline. His career is marked by a strong commitment to advancing medical science, evidenced by his contributions to the development of numerous therapies across multiple therapeutic areas, including oncology, immunology, and infectious diseases. Dr. Leonard's academic background is equally impressive; he earned his M.D. from the University of Chicago and completed his residency in internal medicine at Massachusetts General Hospital, followed by a fellowship in infectious diseases at Stanford University. At Intellia Therapeutics, Dr. Leonard is at the helm of a company that is revolutionizing the field of gene editing. Under his leadership, Intellia has made significant strides in developing CRISPR-based therapies, with a robust pipeline targeting a range of genetic diseases. His strategic vision and scientific expertise have been instrumental in securing key partnerships and advancing the company's clinical programs. Dr. Leonard's dedication to bringing life-changing therapies to patients is evident in his leadership approach, which emphasizes innovation, collaboration, and a relentless focus on improving patient outcomes.